Image credit: Canva
Cervical cancer forms in the tissues of the cervix. It can be slow-growing, but it can also spread to other parts of the body. A clinical trial led by James L. Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology, is researching combination immunotherapy for adults with recurrent or metastatic cervical cancer.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Erica Redmond at erica.redmond@nih.gov
Clinicaltrials.gov identifier: NCT06157151
NCI Protocol ID: IRB001778
Official Title : A Randomized, Open-label, Two-arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy in Patients With Recurrent or Metastatic Cervical Cancer.
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
